Mr. Hugh Rogers reports

XPHYTO PROVIDES COMMENTS ON PROMOTIONAL AND MARKETING ACTIVITY

At the request of OTC Markets, XPhyto Therapeutics Corp. has provided comments regarding recent promotional activity with respect to the corporation.

The corporation has been listed on the Canadian Securities Exchange from July, 2019. Since that time, the corporation has engaged various third parties to provide media, marketing and investor relations services. Most of the corporation's promotional activities have been continuing since listing. Most recently, the corporation engaged Investor Channel Inc. in January, 2021, to provide advertising placements and transaction services. All source materials and content for all promotional activity were provided by the corporation and vetted for factual accuracy by a senior officer of the corporation. Payment for promotional activities was made exclusively by the corporation. In connection with the creation of the promotional activity, the corporation through its executive management participated in the creation of promotional materials. The corporation was not involved in the distribution of promotional materials and all promotional activities were undertaken pursuant to written or oral agreements with third party service providers and their subcontractors. The corporation ultimately had control over the content of all promotional activities.

The company was aware of all promotional activities from when such activities were engaged (as set out in the Schedule A below) and confirms that the statements in the promotional activity are not false or misleading. The corporation does not believe that the promotional activity had any material impact on the trading activity of the corporation's shares but rather, the fact that the corporation was developing its products and raising capital was the significant factor in the trading activity of the corporation's shares.

The corporation verifies the truth and accuracy of the facts provided in or through all promotional activities and confirms that, after due inquiry, no third party has paid for or participated in the creation or distribution of promotional activity. The corporation is not aware, after inquiry, if any director, officer, employee or service provider providing promotional activity has traded in the shares of the corporation in the preceding 90 days, save and except for the purchase of 10,000 shares of the corporation on Jan. 7, 2021, by a single service provider who provided promotional activity. The corporation has not issued convertible securities at a discount to market price when such convertible securities were contracted. Schedule A is a list of third party service providers engaged by the corporation to provide promotional activities in the preceding 12 months.

About Xphyto Therapeutics Corp.

Xphyto is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The company has research and development operations in North America and Europe and is currently focused on regulatory approval and commercialization of medical products for European markets.

We seek Safe Harbor.